Trial Search Results

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Stanford Investigator(s):

Intervention(s):

  • Drug: PF-05082566
  • Drug: rituximab
  • Drug: PF-05082566

Phase:

Phase 1

Eligibility


Inclusion Criteria

   - Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor
   malignancy or B cell lymphoma, for which no curative therapy is available. Portion A
   expansion includes patients who have documented disease progression on a checkpoint
   inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types
   include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer
   (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose
   expansion stage are required to provide archival or baseline (obtained during the
   screening period) tumor biopsies.

   - Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which
   no curative therapy is available. Patients enrolled in the expansion cohort must have
   archival tissue available, sampled within 6 months of study entry. The Expansion
   cohort includes patients with FL or DLBCL with relapsed or refractory disease.

   - Measurable disease with at least one extranodal tumor mass >1.0 cm in the greatest
   transverse diameter (GTD) or in the case of malignant lymph nodes >1.5 cm in the GTD.

   - ECOG performance status of ≤ 1.

   - Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ≥ 1.5 x
   109/L, platelet count ≥100 x 109/L, hemoglobin >9.0 g/dL. For Portion B: ANC ≥ 1.0 x
   109/L, platelet count ≥ 75 x 109/L, and hemoglobin ≥ 8.0 g/dL. In both cases, patients
   must be transfusion independent at least 14 days prior to screening.

   - Serum creatinine ≤ 2 x ULN or estimated creatinine clearance ≥ 50 ml/min.

   - Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome
   and AST and ALT ≤ 2.5 x ULN.

Exclusion Criteria

   - Patients with known symptomatic brain metastases requiring steroids.

   - Prior allogeneic hematopoietic stem cell transplant.

   - Immunosuppressive regimens involving systemic corticosteroids within 14 days before
   the first dose of study treatment.

   - Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation
   therapy within 14 days of the first dose of study drug.

   - Autoimmune disorders and other diseases that compromise or impair the immune system.

   - Unstable or serious concurrent medical conditions in the previous 6 months.

   - Prior therapy with any anti CD137 monoclonal antibody.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting